PeptiGrowth Inc. is Launching Novel Synthetic Peptides BMP7 selective inhibitor and BMP4 selective inhibitor

December 12th, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed two novel synthetic peptides, “BMP7 selective inhibitor (product code: PG-005)” and “BMP4 selective inhibitor (product code: PG-006)”, which selectively bind and inhibit BMP7 and BMP4 respectively. We started marketing this product on December 8th, 2022.

Development of Synthetic Peptide Growth Factors by PeptiGrowth

Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.

About BMP7 selective inhibitor and BMP4 selective inhibitor

➢ Selectivity of our products for BMP proteins

Noggin binds to various BMP family proteins and inhibits their cell signaling, and our Noggin-like peptide (product code: PG-004) launched in July 2022 also binds to a wide range of BMP family proteins and shows inhibitory activities. In contrast, our newly developed BMP7 selective inhibitor (PG-005) and BMP4 selective inhibitor (PG-006) are the products with selective inhibitory activities for each of the BMP7 family (BMP5, BMP6 and BMP7) and the BMP4 family (BMP2 and BMP4) respectively. We believe that our PG-005 and PG-006 enables detailed analysis and adjustment of individual BMP signals as well as identification of new cell differentiation pathways, which has been challenging up until today.

➢ Selective inhibition against BMP7 and BMP4

We performed functional comparison tests between our BMP7 selective inhibitor (PG-005, Fig1), BMP4 selective inhibitor (PG-006, Fig2) and commercially available recombinant Noggin by measuring smad1 phosphorylation.

As a result, our BMP7 selective inhibitor showed inhibitory activity against BMP7 but not against BMP4, while BMP4 selective inhibitor showed inhibitory activity against BMP4 but not against BMP7. On the other hand, our Noggin-like peptide (PG-004, Fig.3), which we have previously launched, showed inhibitory activities against both of BMP4 and BMP7.

➢ Product Overview
Product Code: PG-005
Product name: BMP7 selective inhibitor
Product form: Lyophilized
Storage conditions: -20 °C or less
Purity: ≥95% by HPLC
Molecular weight: 2,085.29
Size: 5 μg (volume per a glass vial)

Product Code: PG-006
Product name: BMP4 selective inhibitor
Product form: Lyophilized
Storage conditions: -20 °C or less
Purity: ≥95% by HPLC
Molecular weight: 3,301.59
Size: 5 μg (volume per a glass vial)
*These products can be provided with Animal Component Free (ACF) certificate.

*These products are for testing and research use only (RUO).
*There is a possibility that the specifications will be changed.

➢ To Purchase This Product

If you would like to purchase these products, please contact Peptigrowth’s agent in North America, MIFI Bioceuticals,
at team@mifibioceuticals.com. We can also supply the products in bulk and manufacture GMP-grade products.

Development of other peptides by PeptiGrowth

PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the missions to address various challenges that regenerative medicine and cell therapy industry is facing. We have launched six products so far. Development of other pipeline has also been going well and we plan to launch multiple products including EGF and FGF2 in 2023 and beyond. Details will be updated on its website upon release.

Source: PeptiGrowth